Anne-Sophie de Faucigny
Public Communications Contact at GETLINK SE
Anne-Sophie de Faucigny active positions
| Companies | Position | Start | End |
|---|---|---|---|
| GETLINK SE | Public Communications Contact | 2022-09-30 | - |
Career history of Anne-Sophie de Faucigny
Former positions of Anne-Sophie de Faucigny
| Companies | Position | Start | End |
|---|---|---|---|
Yposkesi
 Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Director/Board Member | 2017-12-31 | 2020-12-31 |
Training of Anne-Sophie de Faucigny
| Institut d’Études Politiques de Toulouse | Graduate Degree |
Statistics
International
| France | 4 |
Operational
| Director/Board Member | 1 |
| Public Communications Contact | 1 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 2 |
| Transportation | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| GETLINK SE | Transportation |
| Private companies | 1 |
|---|---|
Yposkesi
Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Health Technology |
